- Home
- VIVS vs MYNZ Comparison
VIVS vs MYNZ Comparison
Compare VIVS & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VIVS
- MYNZ
- Stock Information
- Founded
- VIVS 2007
- MYNZ 2021
- Country
- VIVS United States
- MYNZ Germany
- Employees
- VIVS N/A
- MYNZ N/A
- Industry
- VIVS Biotechnology: Biological Products (No Diagnostic Substances)
- MYNZ Biotechnology: Pharmaceutical Preparations
- Sector
- VIVS Health Care
- MYNZ Health Care
- Exchange
- VIVS Nasdaq
- MYNZ Nasdaq
- Market Cap
- VIVS 8.1M
- MYNZ 7.9M
- IPO Year
- VIVS N/A
- MYNZ 2021
- Fundamental
- Price
- VIVS $2.31
- MYNZ $1.53
- Analyst Decision
- VIVS
- MYNZ Buy
- Analyst Count
- VIVS 0
- MYNZ 2
- Target Price
- VIVS N/A
- MYNZ $14.00
- AVG Volume (30 Days)
- VIVS 104.1K
- MYNZ 534.4K
- Earning Date
- VIVS 11-12-2025
- MYNZ 12-29-2025
- Dividend Yield
- VIVS N/A
- MYNZ N/A
- EPS Growth
- VIVS N/A
- MYNZ N/A
- EPS
- VIVS N/A
- MYNZ N/A
- Revenue
- VIVS $142,000.00
- MYNZ $659,935.00
- Revenue This Year
- VIVS $42.38
- MYNZ $26.06
- Revenue Next Year
- VIVS $15.42
- MYNZ $4.97
- P/E Ratio
- VIVS N/A
- MYNZ N/A
- Revenue Growth
- VIVS 94.52
- MYNZ N/A
- 52 Week Low
- VIVS $1.41
- MYNZ $1.28
- 52 Week High
- VIVS $21.96
- MYNZ $14.39
- Technical
- Relative Strength Index (RSI)
- VIVS 39.79
- MYNZ 46.59
- Support Level
- VIVS $2.14
- MYNZ $1.51
- Resistance Level
- VIVS $2.44
- MYNZ $1.63
- Average True Range (ATR)
- VIVS 0.24
- MYNZ 0.11
- MACD
- VIVS -0.07
- MYNZ 0.01
- Stochastic Oscillator
- VIVS 13.40
- MYNZ 51.61
About VIVS VivoSim Labs Inc. Common Stock
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.